Her2 survival beyond 5 years from 2006 ASCO

[RobinP]

I thought this was an interesting abstract on her2 relapse beyond 5 years.Of course, it would have been nice too if they had eluded to how many her2+s relapse the first five years.
HER-2 status of the primary breast cancer in patients with relapse at least five years after the initial diagnose.



Abstract No:

10631

Citation:

Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 10631

Author(s):

Z. I. Tomasevic, D. Jovanovic, L. Radosevic-Jelic, Z. Tomasevic, S. Vasovic, L. Stamatovic, S. Jelic, J. Spasic

Abstract:

Background: HER-2 status of the primary breast carcinoma in the subgroup of patients who relapsed after many years is not well known. The aim of this paper is to determine the HER-2 status of the primary breast cancer in patients with late relapse, defined as local recurrence, distant metastases or carcinoma in the contralateral breast, at least five years after the initial diagnosis Methods: During six month period (June-November 2005) 1256 patients were diagnosed with primary or relapsed breast cancer at the IORS. HER-2 (HercepTest, DAKO) status was determined on the archived pathological specimens of patients with late relapse. Results: One hundred eleven patients (111/1256; 8,8%) were diagnosed with late relapse. At the time of the initial diagnose, majority of patients have been treated for early breast carcinoma. Median age at the initial diagnose was 50 years (33-74). Initial tumor characteristic were: ductal carcinoma 49%; lobular carcinoma 41%;cancer mastitis 6,5%;not reported 3,5%; T1 34%; T2 52%; T3 4,5%; T4 6%;unknown 3,5%; Nodal status: positive 73,5%; negative 23%;not reported 3,5% Steroid receptor status: ER and/or PR positive 59%; both negative 14%; unknown 27%. Median time to relapse is 7 years, (range 5-29), the most frequent first relapse sites were: local recurrence (22%); carcinoma of the contralateral breast (18%); bone metastases (18%). Archived pathological specimens are identified for 63/111 (56,7%) patients and HER-2 status of the those primary breast carcinoma is: 0+ 36,5%; 1+ 34,9%; 2+ 9,5%; 3+ 14,2%; Thirty four patients (30,6%) had disease free interval 10 or more years, and HER-2 3+ in this subgroup is 17,6% (6/34). Conclusions: Long disease free interval in breast cancer patients is usually explained by initial more favorable cancer characteristics. Still, a significant percentage (14,2%) of our patients with median time to relapse of 7 years, initially had breast cancers with HER-2 3+.

[RhondaH]

we need to keep in mind that this was PRE Herceptin for early stage AND we don't know what treatments they received. Thank you for an interesting article.

Rhonda

[Bev]

It was interesting that the hormone negs did so much better. Without the knowledge of what happened the first few years, I don't know. BB

[RhondaH]

it will be interesting to see what happens to the "next generation" of Her2 women.

Rhonda